total
dromedari
camel
camelu
dromedariu
serum
sampl
systemat
sampl
dubai
unit
arab
emir
surround
area
collect
n
collect
n
total
number
camel
area
fecal
sampl
also
avail
collect
n
obtain
anim
collect
born
rais
dubai
central
veterinari
research
laboratori
test
camel
per
year
contact
camel
camel
collect
race
camel
age
rang
year
camel
collect
adult
livestock
camel
origin
purchas
saudi
arabia
sudan
pakistan
oman
dromedari
camel
blood
obtain
routin
health
screen
jugular
vein
punctur
accord
standard
veterinari
procedur
train
personnel
serum
sampl
anim
owner
request
sampl
code
anonym
sampl
obtain
store
analysi
comparison
serum
sampl
c
bactrianu
camel
zoolog
garden
germani
includ
studi
serum
sampl
ship
agreement
german
import
regul
screen
purpos
rifa
use
brief
vero
cell
transfect
eukaryot
express
vector
contain
complet
spike
sequenc
merscov
human
cell
fix
posttransfect
icecold
acetonemethanol
store
dri
serum
sampl
appli
dilut
h
optim
reduc
nonspecif
reaction
maintain
sensit
secondari
detect
conduct
use
goat
antillama
igg
fluorescein
antibodi
neg
serum
sampl
dilut
also
test
confirmatori
assay
base
protein
microarray
perform
describ
use
spike
subunit
merscov
human
sarscov
serum
sampl
use
dilut
microarray
chip
rel
light
unit
determin
use
secondari
cyanin
goat
antillama
igg
merscov
ifa
infect
vero
cell
conduct
describ
use
commerci
avail
merscov
ifa
slide
euroimmunag
germani
serum
sampl
use
dilut
secondari
detect
conduct
use
goat
antillama
fluorescein
igg
dilut
agrisera
sweden
serum
neutral
test
conduct
describ
use
vero
merscov
pt
bcov
cell
reduc
volum
serum
need
neutral
test
perform
format
reaction
contain
pfu
merscov
strain
bcov
nebraska
strain
medium
mix
camel
serum
dilut
serumfre
dulbecco
minimum
essenti
medium
start
dilut
incub
h
well
infect
h
mixtur
supernat
remov
fresh
complet
dulbecco
minimum
essenti
medium
ad
assay
termin
fixat
paraformaldehyd
min
stain
crystal
violet
day
neutral
titer
defin
serum
dilut
reduc
cytopath
effect
parallel
well
viral
rna
extract
serum
fecal
sampl
use
magna
pure
system
roch
basel
switzerland
input
volum
serum
fecal
materi
suspend
phosphatebuff
salin
buffer
elut
volum
serum
fecal
suspens
identifi
covspecif
nucleic
acid
gener
cov
pcr
perform
describ
follow
subsequ
sanger
sequenc
amplifi
dna
character
reactiv
camel
serum
sampl
merscov
differ
assay
format
chose
camel
serum
sampl
weak
strong
reactiv
predetermin
use
simpl
ifa
serum
sampl
titrat
dilut
seri
appli
assay
reactiv
pattern
merscov
spike
protein
merss
compar
human
spike
protein
previou
studi
human
use
instead
bcov
initi
experi
serolog
indistinguish
bcov
subject
handl
restrict
german
anim
diseas
protect
act
overal
titer
merss
higher
sever
serum
sampl
react
exclus
virus
tabl
suggest
absenc
gener
crossreact
spike
protein
virus
ifa
typic
pattern
reactiv
observ
camel
serum
sampl
shown
figur
panel
previous
publish
microarraybas
assay
use
receptorbind
spike
subunit
merscov
human
sarscov
also
evalu
contrast
previou
studi
chose
lower
fluoresc
intens
cutoff
instead
rel
fluoresc
unit
rfu
maxim
sensit
therebi
challeng
target
specif
mer
ifaneg
serum
sampl
signal
intens
rfu
serum
dilut
tabl
rifaposit
serum
sampl
satur
signal
rfu
reactiv
pattern
across
serum
panel
compar
rifa
expect
serum
sampl
neg
control
antigen
comparison
typic
reactiv
pattern
microarray
ifa
shown
figur
panel
b
result
rifa
protein
microarray
highli
congruent
panel
camel
serum
sampl
addit
test
commerci
avail
ifa
use
cell
infect
merscov
vifa
euroimmun
ag
use
whole
viru
provid
addit
structur
nonstructur
protein
antigen
includ
envelop
membran
nucleocapsid
divers
replicas
protein
howev
conserv
featur
nonstructur
protein
among
even
distantli
relat
cov
crossreact
possibl
assay
test
panel
camel
serum
sampl
vifa
titer
correspond
well
titer
determin
rifa
gener
equal
higher
titer
rifa
tabl
despit
absenc
crossreact
serum
sampl
test
figur
panel
previou
studi
vifa
show
falseposit
result
human
serum
sampl
particular
use
lower
dilut
confirm
result
affin
assay
result
function
test
determin
endpoint
viru
neutral
titer
use
microneutr
test
merscov
bcov
anim
merscov
serum
neutral
titer
higher
titer
bcov
serum
sampl
tabl
high
ifa
titer
gener
correspond
high
neutral
titer
except
bcov
serum
sampl
diverg
affin
neutral
assay
result
wane
neutral
antibodi
activ
infect
occur
long
ago
neutral
assay
confirm
absenc
crossneutr
merscov
bcov
antibodi
either
direct
even
low
dilut
howev
sampl
tabl
neutral
bcov
dilut
despit
show
neg
result
serolog
assay
find
indic
nonspecif
neutral
activ
might
encount
camel
serum
sampl
suggest
higher
serum
dilut
use
conduct
critic
investig
viral
reservoir
studi
basi
valid
studi
investig
collect
serum
sampl
dromedari
camel
unit
arab
emir
sampl
initi
screen
chose
rifa
proven
sensit
decreas
chanc
gener
falseposit
result
camel
serum
sampl
unit
arab
emir
germani
initi
screen
dilut
total
serum
sampl
collect
show
posit
result
tabl
seropreval
higher
collect
exclus
adult
anim
collect
collect
young
race
camel
year
age
collect
clear
seroposit
result
includ
dromedari
camel
serum
sampl
obtain
collect
serum
sampl
german
zoolog
garden
test
dilut
show
reactiv
rifa
retest
lower
dilut
confirm
absenc
reactiv
serum
sampl
subcollect
contain
serum
sampl
anim
born
never
left
close
anim
research
facil
dubai
anim
seroneg
confirmatori
microneutr
test
conduct
dilut
ifareact
serum
sampl
high
dilut
chosen
basi
observ
high
level
neutral
serum
activ
camel
serum
sampl
high
neutral
titer
tabl
serum
sampl
neutral
titer
rang
rifaposit
serum
sampl
neutral
titer
rule
crossreact
studi
addit
exposur
camel
bcov
serum
sampl
merscov
neutral
titer
test
use
bcovspecif
microneutr
assay
dilut
total
serum
sampl
concomit
neutral
activ
bcov
tabl
serum
sampl
merscov
neutral
antibodi
titer
total
concomit
neutral
activ
bcov
fecal
sampl
avail
dromedari
camel
collect
sampl
test
use
subfamili
broadrang
revers
transcript
pcr
rtpcr
highli
sensit
rtpcr
specif
genu
betacoronaviru
phylogenet
lineag
c
assay
specif
viral
rnadepend
rna
polymeras
gene
two
posit
fecal
sampl
identifi
assay
sequenc
amplifi
cdna
fragment
nt
nt
identifi
sequenc
ident
bcov
strain
mebu
genbank
access
no
confirm
viru
ident
amplifi
region
within
spike
protein
gene
posit
bcov
strain
mebu
use
rtpcr
sequenc
amplicon
anim
ident
nucleotid
level
bcov
strain
mebu
indic
presenc
bcov
camel
report
test
serum
sampl
way
rtpcr
obtain
uniformli
neg
result
shown
dromedari
camel
unit
arab
emir
countri
human
case
merscov
infect
antibodi
neutral
merscov
high
rate
antibodi
detect
serum
sampl
obtain
serum
sampl
obtain
year
earlier
indic
longstand
presenc
merscov
close
relat
viru
dromedari
camel
region
data
add
previou
studi
group
other
report
wide
antibodi
preval
camel
variou
region
includ
oman
egypt
canari
island
lower
seropreval
collect
contain
young
race
camel
suggest
anim
might
infect
juvenil
howev
limit
data
made
avail
owner
definit
statement
await
confirm
absenc
antibodi
control
cohort
germani
might
explain
fact
anim
belong
differ
camelid
speci
c
bactrianu
vs
c
dromedariu
howev
merscov
highli
conserv
receptor
structur
assign
high
prioriti
hypothesi
close
relat
camel
speci
c
bactrianu
less
suscept
c
dromedariu
camel
merscov
differ
antibodi
preval
rate
might
reflect
restrict
geograph
distribut
viru
correspond
previou
find
rel
lower
preval
antibodi
mer
cov
camel
canari
island
isol
point
origin
africa
mani
year
therefor
virus
camelid
might
spread
across
region
cover
least
eastern
arabian
peninsula
includ
oman
unit
arab
emir
egypt
morocco
antibodyposit
camel
describ
reusken
et
al
origin
high
rate
antibodi
preval
contemporari
serum
sampl
sampl
suggest
viru
spread
camelid
time
howev
recognit
camelid
bona
fide
reservoir
merscov
await
sequenc
camelidassoci
mersrel
cov
context
anim
infect
conspecif
virus
regard
reservoir
given
viru
although
neutral
assay
provid
evid
infect
viru
belong
serotyp
systemat
studi
defin
whether
serotyp
correl
cov
speci
nevertheless
sever
cov
clade
serotyp
defin
neutral
assay
includ
viral
speci
member
speci
betacoronaviru
includ
bcov
show
crossneutr
close
relat
sister
speci
human
show
crossneutr
felin
cov
fcov
compris
subserotyp
show
limit
crossreact
consid
viru
speci
transmiss
gastroenter
viru
swine
show
effici
crossneutr
fcov
subserotyp
classifi
speci
fcov
even
though
carri
differ
host
human
cov
form
close
relat
sister
taxa
show
crossneutr
concordantli
form
differ
speci
genet
criteria
therefor
find
high
neutral
antibodi
titer
camelid
suggest
evidentiari
presenc
virus
conspecif
merscov
camelid
final
confirm
depend
identif
viru
sequenc
camelid
expect
close
relat
humanspecif
merscov
sequenc
camel
probabl
acquir
merscov
unknown
time
potenti
sourc
includ
bat
famili
vespertilionida
viru
close
phylogenet
relationship
merscov
detect
viru
carri
vespertilionid
bat
genu
neoromicia
confirm
conspecif
merscov
lineag
c
betacoronavirus
bat
taxa
also
propos
relat
merscov
howev
although
virus
cluster
phylogenet
merscov
conspecif
merscov
basi
sequenc
distanc
criteria
propos
drexler
et
al
vespertilionid
bat
includ
genu
neoromicia
viru
conspecif
merscov
differ
human
merscov
even
formal
member
speci
observ
degre
sequenc
diverg
viru
merscov
make
direct
recent
transmiss
bat
human
seem
unlik
nevertheless
exclud
avail
data
viru
sourc
popul
bat
detect
exampl
recent
investig
rhinolophu
bat
china
identifi
virus
close
relationship
bona
fide
ancestor
sarscov
virus
describ
mani
studi
yield
conspecif
yet
less
relat
virus
studi
virus
civet
cat
deem
intermediari
host
transit
sarscov
bat
human
still
close
relat
human
sarscov
even
closest
batborn
viru
camelid
function
intermediari
host
similar
manner
expect
viru
camelid
closer
phylogenet
relationship
batborn
cov
thu
easili
detect
avail
rtpcr
larger
studi
confirm
presenc
merscov
camelid
receiv
high
prioriti
defin
anim
reservoir
merscov
possibl
control
measur
vaccin
control
anim
movement
howev
implement
control
measur
whether
camelid
continu
sourc
infect
human
need
firmli
establish
